CAJ | 학술논문

目的：前瞻性研究动态增强MRI对乳腺癌新辅助治疗疗效评价以及分子标志物对新辅助治疗疗效的预测价值。方法以2010年8月至2013年8月各合作中心接受新辅助治疗的早期乳腺癌患者为研究对象，分析治疗前后动态增强MRI和组织病理疗效评价间的相关性，并研究肿瘤分子标志物对新辅助治疗获益的预测价值。结果 MRI评价新辅助治疗有效和组织病理评价有效之间的符合率为94.55％，二者具有高度一致性（Kappa系数0.2528，P＜0.001）。免疫组化孕激素受体（PR）阴性、人表皮生长因子受体2（HER-2）阳性表达以及高Ki-67指数与新辅助治疗pCR显著相关（P＜0.05）。结论动态增强MRI对新辅助治疗疗效评价与组织病理评价具有良好相关性，PR阴性、HER-2阳性以及高Ki-67指数对新辅助治疗pCR具有预测价值。
목적：전첨성연구동태증강MRI대유선암신보조치료료효평개이급분자표지물대신보조치료료효적예측개치。방법이2010년8월지2013년8월각합작중심접수신보조치료적조기유선암환자위연구대상，분석치료전후동태증강MRI화조직병리료효평개간적상관성，병연구종류분자표지물대신보조치료획익적예측개치。결과 MRI평개신보조치료유효화조직병리평개유효지간적부합솔위94.55％，이자구유고도일치성（Kappa계수0.2528，P＜0.001）。면역조화잉격소수체（PR）음성、인표피생장인자수체2（HER-2）양성표체이급고Ki-67지수여신보조치료pCR현저상관（P＜0.05）。결론동태증강MRI대신보조치료료효평개여조직병리평개구유량호상관성，PR음성、HER-2양성이급고Ki-67지수대신보조치료pCR구유예측개치。
Objective To explore the value of dynamic contrast-enhanced magnetic resonance imaging ( DCE-MRI) in monitoring therapy responses and analyze the predictive value of tumor biomarkers in neoadjuvant chemotherapy for breast cancer.Methods From August 2010 to August 2013, the patients diagnosed as primary invasive breast cancer were admitted into this multi -center study.All of them received 6 cycles of neoadjuvant chemotherapy and DCE-MRI during the procedure and underwent surgery.The associations between clinical therapy response and pathologic response as well as predictive factors were analyzed.Results As for evaluating neoadjuvant treatment response ,DCE-MRI had statistically significant correlations with histopathology.PR negativity , HER-2 over-expression and high Ki-67 index were statistically correlated with pathologic complete response (pCR) ( P<0.05).Conclusion DCE-MRI is a reliable method of assessing the response of neoadjuvant therapy for breast cancer .And the immunohistochemistry status of PR , HER-2 and Ki-67 were related with pCR.